Enduring Material

PsoundBytes CME- It’s Time for a Change: IPC Psoriasis Severity Reclassification
View Activity Info
Enter Basic User Info
View Content
Take Post Test
Create Account
Done
View Activity Info
Continue to Enduring Material
 
 
National Psoriasis Foundation

6600 SW 92nd Ave., Suite 300
Portland, OR 97223-7195
General Information
Wednesday, June 9, 2021 - Thursday, June 9, 2022
National Psoriasis Foundation
Virtual Conference Room
Psound Bytes CME Podcast
National Psoriasis Foundation
Objectives
  • Increased understanding of how gut microbiomics can affect psoriatic disease
  • Understanding of how current psoriasis categorization can affect treatment
  • Understanding the proposed new recategorization of psoriasis severity
Presentations and Speakers
PsoundBytes CME- It’s Time for a Change: IPC Psoriasis Severity Reclassification
  • Andrew Blauvelt, MD, MBA - Oregon Medical Research Center
  • Bruce Strober, MD
Available Credits/Points
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.5 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Psoriasis classification is more than a BSA or PASI score. Listen as Dr. Bruce Strober, Clinical Professor of Dermatology at Yale University, New Haven, CT and Dr. Andrew Blauvelt, President, Oregon Medical Research Center in Portland, OR discuss the International Psoriasis Council’s rationale for changing psoriasis severity classification for treatment decisions and clinical trials.
Disclosure Statements
NPF Staff/Planning Committee, has disclosed no relevant financial relationships with commercial interests.
Speakers:
Andrew Blauvelt, MD, MBA has disclosed a relevant financial relationship with a commercial interest in the last 12 months:
  • Abbvie - Speaking
  • Aclaris, Almirall, Avena, Athenex, Boehringer, Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly & Company, Forte Galderma, Incyte, Janssen, Leo, Novartis, Ortho, Pfizer, Rapt, Regeron, Sandoz, Sanofi, Genzyme, SunPharma & UCB Pharma - Scientific advisor &/or clinical study investigator
Bruce Strober, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol-Myers-Squibb, Connect Biopharma, Dermavant, Equillium, Janssen, Leo, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera, Novartis, Pfizer, GlaxoSmithK - Consulting - Relationship Has Not Ended
  • AbbVie, Eli Lilly, Janssen, Sanofi-Genzyme - Speaking - Relationship Has Not Ended
  • CorEvitas (formerly Corrona) Psoriasis Registry - Co-Scientific Director - Relationship Has Not Ended
  • Dermavant, AbbVie, Corrona Psoriasis Registry, Dermira, Cara, Novartis - Investigator - Relationship Has Not Ended
  • Connect Biopharma - Shareholder - Relationship Has Not Ended
  • Journal of Psoriasis and Psoriatic Arthritis - Editor-in-Chief - Relationship Has Not Ended

Accreditation Statement
  • The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Test Information
100 %
6/9/2021
Continue to Enduring Material